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A B S T R A C T
Purpose
To evaluate the efficacy of a psychoeducational intervention in improving cancer-related fatigue.
Patients and Methods
This randomized controlled trial involved 109 women commencing adjuvant chemotherapy
for stage I or II breast cancer in five chemotherapy treatment centers. Intervention group
patients received an individualized fatigue education and support program delivered in the
clinic and by phone over three 10- to 20-minute sessions 1 week apart. Instruments included
a numeric rating scale assessing confidence with managing fatigue; 11-point numeric rating
scales measuring fatigue at worst, average, and best; the Functional Assessment of Cancer
Therapy–Fatigue and Piper Fatigue Scales; the Cancer Self-Efficacy Scale; the European
Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30; and
the Hospital Anxiety and Depression Scale. For each outcome, separate analyses of
covariance of change scores between baseline (T1) and the three follow-up time points (T2,
T3, and T4) were conducted, controlling for the variable’s corresponding baseline value.
Results
Compared with the intervention group, mean difference scores between the baseline (T1)
and immediate after the test (T2) assessments increased significantly more for the control
group for worst and average fatigue, Functional Assessment of Cancer Therapy–Fatigue, and
Piper fatigue severity and interference measures. These differences were not observed
between baseline and T3 and T4 assessments. No significant differences were identified for
any pre- or post-test change scores for confidence with managing fatigue, cancer self-
efficacy, anxiety, depression, or quality of life.
Conclusion
Preparatory education and support has the potential to assist women to cope with
cancer-related fatigue in the short term. However, further research is needed to identify
ways to improve the potency and sustainability of psychoeducational interventions for
managing cancer-related fatigue.
J Clin Oncol 23:6027-6036. © 2005 by American Society of Clinical Oncology
INTRODUCTION
Fatigue is the most frequently reported
side effect of cancer treatment, with a
prevalence ranging from 25% to 99% at
different times in treatment programs and
across differing diagnostic groups.1 For
some patients, cancer-related fatigue will
persist for considerable periods of time
at levels higher than those reported by
healthy controls.2-4 Fatigue has also been
identified as the most problematic side
effect for women with breast cancer.5 Al-
though the need for interventions to ad-
dress the problem of cancer-related fatigue
has been well documented,6,7 high-level
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evidence to guide fatigue management for people with can-
cer is limited.
Current clinical guidelines for reducing fatigue empha-
size the importance of identifying the cause of the problem
and correcting it.8 However, given the multidimensional
nature of fatigue, it is also likely that a range ofmore general
nonpharmacologic approaches will have potential as ad-
junctive measures in reducing the intensity and impact of
this symptom.9 For example, there is an emerging evidence
base to support the use of structured exercise programs for
fatigue management in selected populations. A recent re-
view of evidence for exercise as an intervention identified 20
experimental studies providing strong support for the pos-
itive effects of a range of activity- and exercise-based inter-
ventions formanagement of cancer-related fatigue.10 Other
studies have reported that preparatory information for pa-
tients before undergoing treatments that induce fatigue can
be beneficial11-13 and have suggested that it may be helpful
just to acknowledge that fatigue is a symptom worthy of
intervention simply by asking about it.14,15 A recent ran-
domized controlled trial has also demonstrated that energy-
conservation strategies, such as priority setting, delegation,
and planning of activities, were effective in achieving a
statistically significant improvement in fatigue levels for
patients who received the intervention compared with pa-
tients who did not receive the intervention.16 Despite the
central role that educative and supportive interventions
have in a comprehensive fatigue-management plan, guide-
lines to assist health care professionals to incorporate these
fundamental strategies into day to day practice are limited.
The purpose of this study is to evaluate the efficacy of a brief
targeted intervention that incorporates educative and sup-
portive strategies to assist patients to develop knowledge
and skills to engage in self-care behaviors that have the
potential to minimize specific factors that may contribute
to increased levels of fatigue, including decreased mobility
or activity, ineffective use of available energy reserves, sleep
disturbances, and anxiety or psychological concerns.17
PATIENTS AND METHODS
Study Design
A multicenter, randomized, controlled design with pre- and
post-test follow-ups was used. Participants were outpatients with
breast cancer who were receiving adjuvant treatment at five day-
treatment units in three major metropolitan hospital settings.
During a 24-month data collection period from November
2000 to October 2002, all women more than 18 years of age with
stage I or II breast cancer whowere commencing adjuvant chemo-
therapy at any of the centers were approached at their first treat-
ment visit for entry onto the study. Women were admitted to the
study if they had an Eastern Cooperative Oncology Group perfor-
mance rating of one or two and their hemoglobin level was at least
11.6 g/mL at recruitment. Baseline assessment was completed at
the first treatment visit. The patientwas then randomly assigned to
intervention or control conditions through a central telephone
system using computer-generated random numbers. Group allo-
cation was concealed from research assistants involved in recruit-
ment and the baseline and follow-up assessments.
A sample size of 35 patients per group was estimated as
necessary to detect a significant difference in treatment effects on
fatigue measures with 80% power and type I error of 5% (two
sided). This allowed for the nondirectional detection of an effect
size in line with the order of magnitude reported in a previous
study18 and is close to an effect size conventionally defined by
Cohen19 as large. To compensate for attrition and nonassessable
patients, 110 patients were recruited to the study.
Figure 1 presents the time points for pre- and postinterven-
tion assessments for the study. All patients completed baseline
assessments (T1) at the first treatment visit. Because patients re-
ceiving chemotherapy face a range of unfamiliar, highly stressful
experiences, especially at their first treatment visit, the first con-
trol/intervention session was conducted at the second treatment
visit to minimize the effect of high initial levels of anxiety on the
patient’s ability to participate in the intervention. Follow-up as-
sessment was conducted on the day of each subsequent treatment
cycle to minimize the confounding effects of treatment. As such,
at T2 and T3, all assessments were conducted on the day of che-
motherapy. For those patients who were commencing radiother-
apy at T3 or T4, assessment was conducted on the first day of a
course of radiotherapy. For those patients who were commencing
Fig. 1 Time points for pre- and postintervention assessments by treatment group. radio, radiotherapy; chemo, chemotherapy.
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radiotherapy at T3, T4 assessments were conducted 2 weeks after
completion of radiotherapy.
Because there were similar numbers of patients who had
received radiotherapy in both the intervention and control
groups, any treatment-related differences between groups are ex-
pected to be similar. Secondary analyses were also conducted to
identify any interaction effects resulting from these differing treat-
ment programs.
Intervention
The psychoeducational intervention aimed to improve pa-
tients’ knowledge and skills to enable them to perform self-care
behaviors designed to minimize fatigue and was based on Green’s
PRECEDE (Predisposing, Reinforcing, and Enabling Causes in Edu-
cational Diagnosis and Evaluation) model of health behavior.20 This
model identifies various factors that may potentially influence a
health behavior, which, in this case, is the use of effective strategies to
reduce fatigue, including self-care actions for promoting sleep and
rest, promoting a balance between activity and exercise, conserving
energy, and promoting restorative activities. The influencing factors
targeted by the intervention included beliefs, attitudes, and percep-
tions thatmight facilitate or hinder a person’smotivation to perform
the desired behaviors; skills and resources necessary to perform the
behaviors; and feedback provided by family or health professionals
that might influence continuance or discontinuance of the behav-
iors. Thus, the intervention involved three individualized sessions
tailored to the patient’s specific needs and circumstances and was
designed to target these influencing factors. It incorporated the
techniques of information giving, problem solving, rehearsal, and
reinforcement. The first session was, on average, 20 minutes in
length and delivered face to face in the clinic at the patient’s second
course of chemotherapy.
The second and third sessions were conducted by phone 1
week apart and were, on average, 10 minutes in length. The initial
session focused on identifying individual fatigue-management
needs and the meaning and impact of fatigue on the patient’s life.
Protocols were developed to guide the specific questioning and the
strategies used by nurses in response to individual fatigue-
management needs. The protocols included both a guide to the
overall structure and process of the intervention, as well as content
to guide possible fatigue-management actions to be used for spe-
cific problems, including lack of knowledge about fatigue, reduced
activity, sleep disturbance, anxiety, nutritional disturbance, and
inadequate communication about fatigue. An extract from the
intervention protocols, outlining the overall structure of the inter-
vention, is presented in Table 1. To supplement the face-to-face
interactions, written patient information was given in the form of
a patient booklet developed from materials published by the
Oncology Nursing Society.21 The patient booklet was also used
to record additional individualized fatigue-management strat-
egies. The two booster sessions were conducted at 1-week in-
tervals by phone and were aimed at review of the patients’
fatigue-management plan, identification of factors facilitating
and hindering use of recommended fatigue-management ac-
tions, and reinforcement.
Control
Women allocated to the control group received general can-
cer education sessions equivalent in number and timing to the
sessions that were provided for the intervention group. This in-
volved an oncology nurse (not the interventionnurse) talkingwith
the control group patients about general issues associated with
living with cancer and providing them with a cancer information
booklet containing general information about cancer published by
the local cancer society. The control sessions were delivered in one
face-to-face session, followed by two phone sessions at 1-week
intervals. To facilitate standardization and quality control in de-
livery of interventions, a maximum of two oncology nurses were
used at each site for administration of fatigue intervention ses-
sions, and one oncology nurse was used at each site for delivering
the control sessions. All nurses underwent a training program
regarding the research program and the fatigue management or
control intervention (whichever was relevant to their role). Nurses
delivering the fatigue interventionwere also providedwith supple-
mentary reading materials and standardized protocols to guide
selection of fatigue-management strategies. Ongoing support was
Table 1. Extract From Intervention Protocols
1. Preassessment:
● Review of patient history and patient responses to the fatigue questionnaire
2. Introduction and establishing a relationship:
● Check this is an appropriate time to conduct the intervention session
● Use the script, which outlines aims of the intervention as a guide
3. Analysis of the problem and the individual issues for the patient:
● Ask selected questions to identify specific concerns
4. Definition of the problems and working through them:
● Reflect/check with patient on their key concerns/issues on relating to fatigue management
● Prepare a personalized fatigue management plan (use Fatigue Management Protocols included in Appendix as a guide)
● Guide the patient through the fatigue information booklet, highlighting information of particular relevance to the patient
5. Review and reinforcement:
● Summarize main issues discussed
● Provide opportunity for patient to ask questions
● Check for any additional concerns that the patient may have
● Provide encouragement to apply strategies; encourage rehearsal/practice of strategies
● Discuss purpose and arrange follow-up session
Protocols relating to the following specific factors are included in the Appendix: lack of knowledge about fatigue, reduced activity, sleep disturbance,
anxiety, nutritional disturbance, inadequate communication about fatigue.
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provided to both intervention and control nurses through regular
discussion with the investigators, usually on a monthly basis.
Instruments
Datawere collected using a structured questionnaire. Consis-
tentwith themodel of health behavior ofGreen et al,20 the primary
end points for the study included use of fatigue-management
behaviors, confidencewithmanaging fatigue, and fatigue intensity
and impact. In addition, secondary outcomes relating to self-
efficacy with coping with cancer, quality of life, and anxiety and
depression were also assessed.
Fatigue-management behaviors. A list of 10 self-care actions
patients may use to manage fatigue was developed from the liter-
ature. Patients were asked to indicate (yes or no) whether they had
used these actions in the week before interview andwhether health
care professionals had recommended use of the actions during the
past week. In addition, patients were asked to indicate whether
they had spoken to a list of health care professionals about fatigue
in the week before interview. On the basis of the responses to these
items, use of fatigue behaviors in the week before interview was
measured by creating three separate indices.
Confidence with managing fatigue. Patients were asked to
rate how confident they felt managing fatigue on an 11-point
numeric rating scale ranging from 0 (not at all confident) to 10
(very confident).
Fatigue experiences. Four 11-point numeric rating scales
ranging from 0 (no fatigue) to 10 (fatigue as bad as you can
imagine)were included to assess levels of fatigue atworst, best, and
average in the past week and currently. In addition, 11-point
numeric rating scales included in the Revised Piper Fatigue Scale22
were used to assess distress associated with fatigue (0  no dis-
tress, 10  a great deal of distress), severity of fatigue (0  mild,
10  severe), and the impact of fatigue (0  none, 10  a great
deal) on four aspects of daily life during the past week. The Func-
tional Assessment of Cancer Therapy–Fatigue was also used.23
This scale asks patients to rate the extent to which they had expe-
rienced each of 20 fatigue-related symptoms and experiences in
the past 7 days using a numeric scale ranging from 0 (not at all) to
4 (very much).
Cancer self-efficacy, quality of life, and psychological well-being.
Self-efficacy with coping with cancer was assessed using a 24-item
instrument developed in earlier pilot studies (Campbell et al,
unpublished report). The scale asks patients to indicate, on a scale
ranging from 0 (not at all confident) to 10 (very confident), how
certain they are that they can deal with a range of challenges
experienced by patients with cancer, such as avoiding negative
thoughts, keeping hopeful, and maintaining independence. In the
present study, the cancer self-efficacy scale had a Cronbach’s
alpha of 0.97.
The 30-item European Organisation for Research and Treat-
ment of Cancer Quality of Life Questionnaire C30 (version 3) was
used to measure health-related quality of life in cancer pa-
tients.24 Twenty-eight of the items within this scale are scored
on a 4-point Likert scale, with the global health status and
quality-of-life questions being scored on a 7-point scale. The
14-item Hospital Anxiety and Depression Scale25 was used to
assess anxiety and depression.
Demographic and medical information. Details of patient
demographics, current illness, and treatment plan were obtained
from the patient’s oncologist andmedical records using a standard
data collection form.
Analysis
Data were entered and analyzed using SPSS version 11.5
(SPSS Inc, Chicago, IL). Initially, control and intervention groups
were compared at baseline with respect to demographic andmed-
ical variables to ensure comparability of groups. Scale scores were
then constructed for each of the outcome variables, and reliability
estimates were calculated for each scale. In fatigue scales, a score of
0 was given to patients reporting no fatigue.
Group differences were determined by t tests for the contin-
uous, normally distributed data and by 2 tests for categoric data.
Descriptive statistics were calculated for the intervention and con-
trol groups for each of the four time points to observe trends in
these outcomemeasures over time. Finally, to test each hypothesis,
analysis of covariance of the change scores was conducted, con-
trolling for the corresponding baseline value of the variable to
adjust for any group differences at baseline. At the third follow-up,
some patients had received radiotherapy treatment. Conse-
quently, analysis of change scores between T4 and baseline also
included a term for the interaction between treatment group allo-
cation and whether patients had received radiotherapy treatment
before T4 assessment. These analyses did not demonstrate any
significant differences in effects for any of the outcome variables.
RESULTS
Figure 2 presents the flow of participants through the study.
Of the 110 eligible patients who were randomly assigned to
the treatment and control groups, one patient did not meet
eligibility criteria and, thus, was excluded. Of the 109 pa-
tients who completed at least one intervention session, 104
patients completed T2 assessment (1 to 2 weeks after com-
pletion of the intervention), 100 patients completed T3
assessment (3 to 4 weeks after T2), and 97 patients com-
pleted T4 assessment (3 to 4 weeks after T3 if chemotherapy
was continuing or 6 to 8 weeks after T3 if a 4- to 6-week
course of radiotherapy had been received since T3).
The demographics of the sample are listed in Table 2.
The age of participants ranged from 26 to 70 years, with a
mean age of 49.4 years (standard deviation  9.4 years).
Many of the women were from relatively high socioeco-
nomic backgrounds, with themedian annual family income
group being $40,001 to $50,000 Australian dollars, and
approximately 65% of the sample had post–high school
qualifications. Most of the women in the study were mar-
ried. The only significant demographic difference between
the intervention and control groups was that the control
group had a higher proportion of participants born over-
seas. Given the small numbers in this group, this difference
was not adjusted for in subsequent analyses.
To be eligible for the study, all women had to have a
diagnosis of early-stage breast cancer and be scheduled to
commence a standard course of adjuvant chemotherapy.
Table3 lists thediagnostic and treatment characteristics for the
109 study participants. There were no significant differences
between the intervention and control groups at baseline for
Yates et al
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these medical variables, including whether or not women re-
ceived a course of radiotherapy during the study period.
Fatigue-Management Behaviors
Patients indicated their use (yes or no) of 10 specified
actions taken to manage fatigue. Overall, the most com-
monly used actions reported at baseline were rest (67%),
hydration (50%), relaxation (48%), exercise (40%), and
listening to music (39%). Use of these actions remained
relatively stable over time, and there were no significant
differences in usage between groups.
Fatigue behavior scores were calculated for each pa-
tient to tally the following for the previous week: the num-
ber of fatigue-management actions used (scores ranging
from 0 none to 10 all listed); (2) the number of health
Fig 2. Flow of participants through the
study. XRT, radiotherapy.
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care professionals with whom the patient had discussed
fatigue (scores ranging from 0 none to 6 all listed); and
(3) the number of fatigue-management actions that had
been recommended (scores ranging from 0  none to
10 all listed). The distributions of scores on these indices
are listed in Table 4. Overall, the mean number of health
care professionals spoken to and the mean number of ac-
tions taken to manage fatigue were low for both groups.
Results in Table 4 report no significant differences be-
tween groups in change scores for communication with
health professionals about fatigue or number of actions
taken tomanage fatigue. However, patients in the interven-
tion group reported a significantly greater mean increase in
the number of actions recommended compared with pa-
tients in the control group between the T1 and T2 and T1
and T4 assessments.
Confidence With Managing Fatigue
The results indicate no significant differences between
control and intervention groups in baseline to postinterven-
tion change scores for confidence withmanaging fatigue.
Fatigue Experiences
Descriptive analyses indicate notable increases inmean
fatigue levels for both groups on all fatigue measures be-
tween T1 and T2, with these higher levels of fatigue persist-
ing at T3 and decreasing only slightly by T4. The results
listed in Table 5 indicate that the increases between the
baseline and immediate postintervention fatigue scores
were significantly greater for the control group when com-
pared with the intervention group for fatigue at worst,
average fatigue, fatigue severity, fatigue interference, and
Functional Assessment of Cancer Therapy. This increase
was consistently more than 50% greater for the control
group when compared with the intervention group. How-
ever, these differences were not sustained for changes be-
tween baseline and T3 or T4.
Secondary Outcomes
There was no significant effect of the intervention for
cancer self-efficacy, quality of life, or psychological well-being.
DISCUSSION
The aim of this study was to evaluate the efficacy of a brief
psychoeducational intervention in improving the use of
fatigue-management behaviors and minimizing the im-
pact of fatigue for women receiving treatment for early-
stage breast cancer. Importantly, our findings suggest that
women who received the intervention received some short-
term benefit in terms of minimization of the intensity and
Table 2. Demographic Profile of the Sample (N  109)
Demographic
Intervention
Patients
(%)
Control
Patients
(%)
Age, years
45 28.3 37.5
46-60 60.4 50.0
61 11.3 12.5
Qualification
No postschool qualification 28.3 33.9
Certificate/degree 71.7 66.1
Country of birth
Australia 86.8 69.6
Other 13.2 30.4
Marital status
Single 7.5 5.4
Married 77.4 73.2
Divorced, separated, or widowed 15.1 21.4
Employment status
Full time 20.8 25.5
Part time/casual 22.6 14.5
Home maker 24.5 25.5
Retired 9.4 12.7
Sick leave/disability 22.6 21.8
Income, Australian dollars
Less than $20,000 21.7 14.9
$20,001-$40,000 15.2 14.9
$40,001-$100,000 45.7 53.2
More than $100,000 17.4 17.0
Living arrangements
Alone 7.5 7.1
With others 92.5 92.9
Have a caregiver
Yes 71.7 73.2
No 28.3 26.8
Caregiver for dependants
Yes 15.1 28.6
No 84.9 71.4
Dependant children
Yes 47.2 44.6
No 52.8 55.4
P  .05.
Table 3. Medical Characteristics of the Sample at
Baseline (T1) (N  109)
Characteristic
Intervention
Patients
Control
Patients
Overall stage of disease, No. 48 51
Stage I, % 8.3 19.6
Stage II, % 91.7 80.4
Type of chemotherapy, No. 53 56
Anthracycline-based protocol, % 71.7 66.1
Nonanthracycline-based protocol, % 28.3 33.9
Radiotherapy received within the follow-up
period for this study, No.
53 56
Yes, % 28.3 32.1
No, % 71.7 67.9
Patients who received radiotherapy within the follow-up period for this
study received the radiotherapy between T3 (commencement of radio-
therapy) and T4 (T2 weeks after radiotherapy).
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impact of fatigue on daily life. Specifically, the study has
found that women in the control group consistently expe-
rienced an increase in levels of fatigue and interference from
fatigue over the treatment course that was consistently
more than 50% greater than that reported by women in the
intervention group. Moreover, patients in the intervention
group reported a significantly greater mean increase in the
number of fatigue-management actions recommended by
healthcareprofessionals comparedwithpatients in thecontrol
groupbetween theT1 andT2 andT1 andT4 assessments. As a
Table 4. Impact of the Intervention on Fatigue Behaviors
Fatigue Behavior
Time 1 Time 2 Time 3 Time 4
No. of
Patients
T2-T1
P
No. of
Patients
T3-T1
P
No. of
Patients
T4-T1
P
Estimated
Marginal
Change
Score
Estimated
Marginal
Change
Score
Estimated
Marginal
Change
Score
No. of
Patients
Mean
No. SD
No. of
Patients
Mean
No. SD
No. of
Patients
Mean
No. SD
No. of
Patients
Mean
No. SD
Mean
Score SEM
Mean
Score SEM
Mean
Score SEM
No. of treatments
used
Intervention 53 3.7 2.8 50 4.3 2.5 50 3.8 2.2 49 3.9 2.7 50 0.7 0.3 50 0.2 0.3 49 0.0 0.3
Control 56 3.8 2.8 54 4.4 2.5 50 4.2 2.4 48 3.7 3.0 54 0.7 0.3 .97 50 0.3 0.3 .89 48 0.3 0.3 .43
Total 109 3.8 2.8 104 4.4 2.5 100 4.0 2.3 97 3.8 2.9
No. of health
professionals
spoken to
Intervention 53 0.9 1.2 50 0.6 0.8 50 0.3 0.7 49 0.3 0.6 50 0.2 0.1 50 0.4 0.1 49 0.4 0.1
Control 56 0.4 1.0 54 0.5 1.0 50 0.4 0.8 48 0.3 0.7 54 0.2 0.1 .88 50 0.2 0.1 .26 48 0.4 0.1 .69
Total 109 0.7 1.1 104 0.5 0.9 100 0.4 0.8 97 0.3 0.6
No. of treatments
recommended
Intervention 53 2.0 2.4 50 3.9 3.1 50 3.2 3.2 49 4.2 3.3 50 2.0 0.4 50 1.5 0.4 49 2.3 0.4
Control 56 1.8 2.2 54 2.3 2.7 50 2.9 2.9 48 2.7 2.9 54 0.4 0.4 .01 50 0.9 0.4 .38 48 0.8 0.4 .02
Total 109 1.9 2.3 104 3.1 3.0 100 3.1 3.1 97 3.5 3.2
Abbreviation: SD, standard deviation.
P  .05.
Table 5. Impact of the Intervention on Fatigue Experiences
Fatigue Behavior
Time 1 Time 2 Time 3 Time 4
No. of
Patients
T2-T1
P
No. of
Patients
T3-T1
P
No. of
Patients
T4-T1
P
Estimated
Marginal
Change
Score
Estimated
Marginal
Change
Score
Estimated
Marginal
Change
Score
No. of
Patients
Mean
Score SD
No. of
Patients
Mean
Score SD
No. of
Patients
Mean
Score SD
No. of
Patients
Mean
Score SD
Mean
Score SEM
Mean
Score SEM
Mean
Score SEM
Worst fatigue
Intervention 51 2.6 3.0 49 3.5 3.2 48 4.1 3.3 47 3.3 3.3 47 1.0 0.4 47 1.5 0.5 46 0.8 0.4
Control 50 1.8 2.5 50 4.5 3.1 47 4.3 3.4 47 3.2 3.0 43 2.6 0.5 .01 42 2.0 0.5 .49 42 1.1 0.5 .65
Total 101 2.2 2.8 99 4.0 3.2 95 4.2 3.3 94 3.3 3.1
Average fatigue
Intervention 51 2.0 2.5 49 2.9 2.8 48 3.2 2.8 47 2.5 2.6 47 1.0 0.4 47 1.3 0.4 46 0.6 0.4
Control 50 1.2 1.7 50 3.5 2.5 47 3.4 2.7 46 2.3 2.3 43 2.3 0.4 .02 42 1.7 0.4 .48 41 0.8 0.4 .65
Total 101 1.6 2.2 99 3.2 2.7 95 3.3 2.7 93 2.4 2.5
Fatigue severity
Intervention 51 1.8 2.6 49 2.7 3.0 48 3.3 3.2 47 2.4 2.8 47 1.0 0.4 47 1.6 0.4 46 0.6 0.4
Control 50 0.9 1.4 49 3.6 3.0 47 3.5 3.2 47 2.3 2.8 42 2.6 0.4 .01 42 1.9 0.5 .59 42 1.3 0.4 .26
Total 101 1.4 2.1 98 3.1 3.0 95 3.4 3.2 94 2.4 2.8
Piper interference
subscale
Intervention 51 2.4 3.2 49 2.7 3.1 48 3.2 3.3 47 2.5 2.8 47 0.5 0.4 47 1.0 0.4 46 0.3 0.4
Control 50 1.3 2.1 49 3.7 3.0 47 3.7 3.2 47 2.3 2.6 43 2.1 0.4 .01 42 1.7 0.5 .25 42 0.7 0.4 .45
Total 101 1.8 2.8 98 3.2 3.1 95 3.5 3.2 94 2.4 2.7
FACT score
Intervention 53 1.1 0.3 50 1.1 0.4 50 1.2 0.5 49 1.2 0.5 50 0.1 0.1 50 0.1 0.1 49 0.1 0.1
Control 56 1.0 0.4 54 1.3 0.6 49 1.3 0.5 48 1.1 0.5 54 0.3 0.1 .04 49 0.2 0.1 .14 48 0.0 0.1 .16
Total 109 1.1 0.3 104 1.2 0.5 99 1.2 0.5 97 1.1 0.5
Abbreviations: SD, standard deviation; FACT, Functional Assessment of Cancer Therapy.
No significant differences in change scores for best fatigue, fatigue now, and distress from fatigue.
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manipulation check, this finding may suggest that the inter-
vention was achieving its desired goal in terms of increasing
patient awareness of potential fatigue-management actions.
Such evidence supports previous research demonstrating the
positive benefits of intervention strategies, such as energy con-
servation and exercise,10,16 and suggests that this brief educa-
tive and supportive intervention has some potential in
reducing cancer-related fatigue. However, the failure to ob-
serve significant postintervention differences for other key
outcomesand the failure toobserve sustainable improvements
in fatigue reduction raises important clinical questions about
the potential efficacy of educative and supportive interven-
tions for complex, multifactorial problems such as fatigue. A
number of possible limitations of this study, including the
effect of some potential confounding variables and measure-
ment error, also need to be considered.
First, it should be noted that the significant effects
observed in this study reflect improvements on the subjec-
tive measures of fatigue experiences, rather than for objec-
tive measures of fatigue-management behavior such as the
number of fatigue-management actions used. As such, one
possible explanation for the findings is that the differences
observed may simply reflect patient expectations that they
would benefit from the intervention or their desire to re-
spond positively to the researchers. To minimize the effects
of such confounding factors, this study included an atten-
tional control group who received a generalized supportive
intervention of equivalent timing to the intervention group,
and nurses who undertook baseline and follow-up assess-
ments were blind to which group patients had been allo-
cated. Despite these measures, the use of self-report as the
sole method for measuring fatigue-management actions
makes it difficult to determine the extent to which any such
placebo effects may be operating. A recent review of studies
investigating placebo effects attributable to the patient-
practitioner relationship concluded that patients’ expectan-
cies are associated with improved outcomes in many trials,
but that, because several of the trials reviewed were not
randomized and the majority reported subjective out-
comes, definitive conclusions could not be made.26
Moreover, other researchers have noted that criteria
for determining the amount of improvement needed for a
symptomatic response to be considered meaningful are not
readily available.27 As such, even though the effect size
observed in the present study was large and acrossmeasures
of interference as well as severity, we cannot rule out the
possibility that at least some of the observed effect is attrib-
utable to patient expectancies. Notwithstanding the meth-
odologic issues raised by these possibilities, the findings of
this study nevertheless underscore the critical importance
of the practitioner-patient relationship to intervention out-
comes. The need to understand precisely what is occurring
in interactions to achieve an observed change is an impor-
tant area of inquiry that has profound implications for
education, research, and practice.
A second explanation for the study findings is that
educative and supportive interventions are simply not pow-
erful enough to detect sustainable improvements, especially
in studies where the sample under investigation is likely to
experience significant variation in levels of fatigue. Further-
more, it is possible that the particular intervention evalu-
ated in the present study is not sufficiently potent to achieve
the degree of behavior change required for complex multi-
factorial symptoms such as fatigue. Potency in this context
might relate to issues such as the intensity, specificity, and
sensitivity of the intervention in achieving the desired out-
comes.28 More specifically, issues such as accuracy and
quality in delivering interventions, the appropriateness of
the strategies used for the problem, and the dose or intensity
of the intervention need to be considered. In the present
study, efforts were made to ensure the accuracy and quality
of the intervention by training the intervention nurses, by
regular informal discussions with intervention nurses, and
by developing evidence-based protocols to provide deci-
sional support tools for these nurses. However, even with
these measures, it is possible that the skills required for
delivering targeted and tailored interventions to address the
complex multifaceted problem of fatigue are quite ad-
vanced and that further ongoing support and training may
be required. For example, additional strategies, such as tape
recording of intervention sessions for peer review, may be
useful to facilitate quality control and gain an understand-
ing of intervention processes.
The development of high-quality decision support
tools, based on an in-depth understanding of the problem,
evidence about the nature of processes through which the
intervention resolves the problem or provides the desired
outcome, and the specific activities constituting the inter-
vention, is also recommended.28 For example, an under-
standing of typical patterns of fatigue across the course of
treatment may suggest that timing of this type of interven-
tion may be one factor influencing its effectiveness. In the
present study, the intervention was delivered early in the
treatment course and was completed before the third cycle
of chemotherapy.
However, our data illustrate that the intensity of fatigue
was far greater later in the course of treatment. As such,
although the intervention studied in the present trialmay be
considered useful from a preparatory perspective, it is pos-
sible that further benefits may have been realized if it was
delivered later in the treatment course when the problem of
fatigue may be more of a priority for patients. Further
booster sessions may also be necessary to complement a
preparatory intervention of this type.
The timing for delivery of follow-up assessments may
also have impacted on the study findings. In the present
study, follow-up assessments were conducted on the last
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day of a 21- or 28-day treatment cycle or 2 weeks after
completion of radiotherapy, when peak effects of chemo-
therapymay have subsided. It may be that the benefit of the
intervention occurs when fatigue levels are at their peak,
usually in the week after chemotherapy administration, and
as a result, the effect of the intervention strategies in this
study was not detected at the time of follow-up assessment
when fatigue levels may have been less intense. In a similar
vein, the dose of the intervention used in the present study
requires some consideration. Studies examining the dose-
response relationship in psychotherapeutic interventions29
have reported a positive relationship between the amount
of psychotherapy and level of patient benefit, with 10% to
18%of patients showing some improvement before the first
session, 18% to 48% improving by the eighth session, and
75% improving by 6 months. However, a more recent sys-
tematic review of patient education interventions in cancer
found that published studies reported, on average, three
contacts per patient, but the length of these contacts was not
described in detail, and no difference in outcomes was
observed according to whether short versus longer infor-
mation packages were provided to patients.30 The dose
dimension of an intervention is rarely discussed in patient
education research despite the critical importance of this
dimension to the translation of findings into practice.
Finally, it is also important to consider whether the
nonsignificant effects observed for the study’s key behav-
ioral outcomes are a result of measurement error. In the
present study, an index of fatigue behaviors was developed
from a review of the literature, whereby patients indicated
by responding yes or no to whether they had used a list of 10
behaviors. However, the behaviors selected and the dichot-
omous measurement scale used may not be valid or sensi-
tive enough to detect actual differences in fatigue self-
management behaviors. Although a number of valid and
reliable measures of health-related attitudes, quality of life,
and other subjective experiences are available to evaluate
outcomes from educational intervention, psychometrically
sound measures of behavioral outcomes are not as readily
available.
This study addresses the problem of fatigue, which is
recognized as one of the most common and distressing
symptoms experienced by people undergoing cancer treat-
ment. Although the limitations of this study need to be
acknowledged, the study represents one of the few con-
trolled trials of educative and supportive interventions de-
signed to build this evidence base. The findings provide
some evidence of the potential benefits of educative and
supportive intervention in ameliorating fatigue for women
receiving treatment for early-stage breast cancer. However,
because the findings indicate that the effectiveness of the
intervention across all outcomes is not consistent and is
only short term, further work is needed to test whether such
interventions are beneficial for patients experiencing differ-
ent levels of fatigue and to improve the sustainability and
potency of interventions of this type. Further research that
focuses on identifying the specific strategies that achieve
behavioral change and the context in which such interven-
tion strategies are best used is required.
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